Phase I study of combined pegylated liposomal doxorubicin with protracted daily topotecan for ovarian cancer

To determine the maximum tolerated dose and dose-limiting toxicity of Doxil with low-dose continuous infusion topotecan and subsequently with low-dose oral topotecan. Other specific aims were preliminary assessment of activity in advanced ovarian and tubal malignancies, pharmacokinetics of oral topo...

Full description

Saved in:

Bibliographic Details
Published in:	Clinical cancer research Vol. 11; no. 16; p. 5912
Main Authors:	Mirchandani, Deepu, Hochster, Howard, Hamilton, Anne, Liebes, Leonard, Yee, Herman, Curtin, John P, Lee, Sang, Sorich, Joan, Dellenbaugh, Cornelia, Muggia, Franco M
Format:	Journal Article
Language:	English
Published:	United States 15.08.2005
Subjects:	Administration, Oral Adult Aged Aged, 80 and over Antineoplastic Combined Chemotherapy Protocols - adverse effects Antineoplastic Combined Chemotherapy Protocols - pharmacokinetics Antineoplastic Combined Chemotherapy Protocols - therapeutic use Diarrhea - chemically induced DNA Topoisomerases, Type I - metabolism DNA Topoisomerases, Type II - metabolism Dose-Response Relationship, Drug Doxorubicin - administration & dosage Doxorubicin - adverse effects Female Humans Immunohistochemistry Infusions, Intravenous Liposomes Male Middle Aged Nausea - chemically induced Neutropenia - chemically induced Ovarian Neoplasms - drug therapy Ovarian Neoplasms - enzymology Ovarian Neoplasms - metabolism Polyethylene Glycols Topotecan - administration & dosage Topotecan - blood Topotecan - pharmacokinetics Treatment Outcome Vomiting - chemically induced
ISSN:	1078-0432
Online Access:	Get more information
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!